Literature DB >> 10451491

Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression.

S Kumar-Singh1, J Weyler, M J Martin, P B Vermeulen, E Van Marck.   

Abstract

Vascular endothelial growth factor (VEGF), acidic and basic fibroblast growth factors (FGF-1 and -2), and transforming growth factor beta (TGFbeta) are potent angiogenic cytokines. Malignant mesothelioma of the pleura presents with a high intra-tumoural microvascular density (IMD) which also has prognostic relevance. This study was designed to verify the immunohistochemical expression of the angiogenic cytokines in mesothelioma as well as in non-neoplastic human mesothelial cells and to study the individual as well as the combined expression of these cytokines in mesothelioma in relation to both IMD and prognosis. In addition, four mesothelioma cell lines were studied by ELISA for the secretion of VEGF and FGF-2 in their supernatants and were shown to contain high levels of both of these cytokines. Immunohistochemically, VEGF, FGF-1 and -2, and TGFbeta immunoreactivity was present in 81, 67, 92 and 96 per cent of mesotheliomas, and in 20, 50, 40, and 10 per cent of samples of the non-neoplastic mesothelium, respectively. Co-ordinate expression of the cytokines was observed whereby mesotheliomas expressed more than one cytokine. The combined immunohistochemical expression levels for all four cytokines correlated significantly with both IMD (p=0.01) and prognosis (p=0. 0013). When studied individually, high FGF-2 expression correlated best with more tumour aggressiveness and worse prognosis for mesothelioma (p=0.0011). There was no significant correlation between prognosis and immunoexpression of VEGF (p=0.07), FGF-1 (p=0.3), or TGFbeta (p=0.1), or between IMD and any of the cytokines studied individually. These data support the assertion that selective angiogenic cytokines might contribute to the progressive changes of mesothelioma by tumour angiogenesis. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10451491     DOI: 10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  41 in total

Review 1.  Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.

Authors:  Roberto E Favoni; Antonio Daga; Paolo Malatesta; Tullio Florio
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  What's the place of immunotherapy in malignant mesothelioma treatments?

Authors:  Marc Grégoire
Journal:  Cell Adh Migr       Date:  2010-01-30       Impact factor: 3.405

3.  Current issues in malignant pleural mesothelioma evaluation and management.

Authors:  Jing Ai; James P Stevenson
Journal:  Oncologist       Date:  2014-07-24

4.  3-O-Methylfunicone, a metabolite produced by Penicillium pinophilum, modulates ERK1/2 activity, affecting cell motility of human mesothelioma cells.

Authors:  E Buommino; I Paoletti; A De Filippis; R Nicoletti; M L Ciavatta; S Menegozzo; M Menegozzo; M A Tufano
Journal:  Cell Prolif       Date:  2010-04       Impact factor: 6.831

5.  Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.

Authors:  Elliot L Servais; Christos Colovos; Luis Rodriguez; Adam J Bograd; Jun-ichi Nitadori; Camelia Sima; Valerie W Rusch; Michel Sadelain; Prasad S Adusumilli
Journal:  Clin Cancer Res       Date:  2012-02-27       Impact factor: 12.531

6.  Murine mesothelioma induces locally-proliferating IL-10(+)TNF-α(+)CD206(-)CX3CR1(+) M3 macrophages that can be selectively depleted by chemotherapy or immunotherapy.

Authors:  Connie Jackaman; Teong L Yeoh; Manyual L Acuil; Joanne K Gardner; Delia J Nelson
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

Review 7.  The network of epithelial-mesenchymal transition: potential new targets for tumor resistance.

Authors:  Danupon Nantajit; Dong Lin; Jian Jian Li
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-01       Impact factor: 4.553

8.  Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.

Authors:  Linda L Garland; Kari Chansky; Antoinette J Wozniak; Anne S Tsao; Shirish M Gadgeel; Claire F Verschraegen; Marco A Dasilva; Mary Redman; David R Gandara
Journal:  J Thorac Oncol       Date:  2011-11       Impact factor: 15.609

Review 9.  Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma.

Authors:  Paolo A Zucali
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 10.  Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.

Authors:  Hui Liu; Licun Wu; Kai Ji; Wei Wang
Journal:  Tumour Biol       Date:  2015-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.